ABT-510 is a molecular therapeutic drug that was the subject of research as a potential treatment for cancer. According to the Journal of Clinical Oncology, ABT-510 is a "subcutaneously (SC) administered nonapeptide thrombospondin analogue."[1][2]
Following inconclusive phase I clinical trials, a 2007 phase II study of ABT-510 for treatment of metastatic melanoma failed to reach its primary endpoint resulting in termination of the study. Only three out of twenty-one patients reached the primary endpoint of progression-free survival at 18 weeks, but these three patients remained progression-free for 21, 34, and 42 weeks. However, biomarker data collected during this study showed a decrease in VEGF-C, circulating endothelial cells, and CD146 and CD34/133 counts, and a maximum tolerated dose has still not been established. Further study could consider a higher dose and/or combination treatment.[3]
References
- ^ "2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)". J. Clin. Oncol. 22 (14S Suppl). July 15, 2004. 3080.
- ^ NCI: ABT-510 Archived September 28, 2007, at the Wayback Machine
- ^ Markovic SN, Suman VJ, Rao RA, et al. (June 2007). "A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma". Am. J. Clin. Oncol. 30 (3): 303–9. doi:10.1097/01.coc.0000256104.80089.35. PMID 17551310.